Driving Biopharmaceutical Advancement of Evidence-Based, Cannabinoid Products
Who We Are
Avicanna Is a Commercial-Stage International Biopharmaceutical Company Focused on the Advancement and Commercialization of Evidence-Based Cannabinoid-Based Products for the Medical and Pharmaceutical Market Segments
Avicanna has an established scientific platform including R&D and clinical development leading to the commercialization of more than thirty proprietary, evidence-based finished products and supporting four commercial stage business pillars.
Corporate Overview
4 commercial stage business pillars
38 commercialized proprietary SKUs
Addressing a global market opportunity
First profitable quarter Q1 2025
Established industry leading scientific infrastructure
JLABS @Johnson and Johnson incubated – at MaRS
Indication specific pharmaceutical pipeline
Partnerships with leading academic and clinical institutions
Robust intellectual property portfolio
Medical Cannabis Products and RHO Phyto – Commercial
Medical Cannabis Pharmacy Platform – Launched August
Pharmaceutical Pipeline – In development and registration stages
Active Pharmaceutical Ingredients – Aureus Santa Marta
Four Commercial Stage Business Pillars
Avicanna’s Scientific Platform Has Resulted In 30+ Proprietary Formulations and Commercial Products
Medical Cannabis Products
Industry Leading Scientific Platform
Setting the Standard in the Cannabinoid Industry with Advanced and Evidence-Based Products
Scientific Platform
R&D Platform Delivering Advanced and Evidence-Based Cannabinoid Products
Commercial Products
10+ Scientists
Pipeline
IP Portfolio including
USPTO granted patents
Grants Awarded Since 2020
All IP and Trade Secrets
World-Class Institutional Collaborations
World-Class Institutional Collaborations
Clinical Development
Setting the Standard in the Cannabinoid Industry on Advanced and Evidence-Based Products
08.08.2021
Products & Pipeline
Serving the Global Marketplace with Proprietary Advanced Cannabinoid-Based Products
